Renesis Tablet 20 mg
Renesis Tablet 20 mg Uses, Dosage, Side Effects, Food Interaction and all others data.
FibroGen completed the phase I single-dose, dose escalation studies as of July 2007. Multiple dose, dose escalation and phase II US studies are listed as ongoing.
FG-4592 represents one of several next generation PHI that has been optimized for multiple pharmacokinetic and pharmacodynamic parameters related to erythropoiesis, including selective inhibition of HIF prolyl and asparaginyl hydroxylases, potency, iron utilization, and ADME. FG-4592 represents one of several next generation HIF-PH inhibitors designed to selectively induce the expression of genes that mediate erythropoiesis for the treatment of anemia.
| Trade Name | Renesis Tablet 20 mg |
| Generic | Roxadustat |
| Roxadustat Other Names | Roxadustat, Roxadustatum |
| Weight | 20 mg |
| Type | Tablet |
| Formula | C19H16N2O5 |
| Weight | Average: 352.346 Monoisotopic: 352.105921623 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | Beacon Pharmaceuticals PLC |
| Available Country | Bangladesh |
| Last Updated: | October 19, 2023 at 6:27 am |
Uses
In clinical development for the treatment of anemia of chronic inflammatory disease.
How Renesis Tablet 20 mg works
FG-4592 is an orally active second generation HIF-PH inhibitor. Preclinical studies show that FG-4592 increases production of endogenous erythropoietin (EPO), increases iron mobilization and utilization, and overcomes the suppressive effects of inflammation on red blood cell production.
Elimination Route
Orally active
Innovators Monograph
You find simplified version here Renesis Tablet 20 mg
